Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | F2R | P25116 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27885277 | 0.88 | CES2 (0.50) | ALDH1A1KDM4ECES2CES1HDAC3 | |
| SCHEMBL7257515 | 0.88 | ALDH1A1 (0.55) | ALDH1A1KDM4ECES2CES1KMT2A | |
| SCHEMBL2654989 | 0.81 | TSHR (0.47) | ALDH1A1F2RKMT2AGAAADRB2 | |
| SCHEMBL9340156 | 0.81 | ALDH1A1 (0.47) | ALDH1A1KDM4EF2RCES2CES1 | |
| SCHEMBL28990208 | 0.81 | ALDH1A1 (0.50) | ALDH1A1KDM4EKMT2AGAATSHR | |
| SCHEMBL5663070 | 0.81 | TSHR (0.55) | ALDH1A1KDM4EKMT2AGAAALOX15 | |
| SCHEMBL27469326 | 0.81 | KDM4E (0.50) | ALDH1A1KDM4ECES2CES1KMT2A | |
| SCHEMBL2080443 | 0.81 | CES2 (0.49) | ALDH1A1CES2CES1KMT2AGAA | |
| SCHEMBL29014554 | 0.80 | F2R (0.46) | ALDH1A1KDM4EF2RKMT2ATSHR | |
| SCHEMBL28547230 | 0.80 | TSHR (0.70) | ALDH1A1KDM4ETSHRTP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023201780-A1 | METHOD FOR PREPARING QUINOLONE COMPOUND AND INTERMEDIATE THEREOF | 重庆文理学院 | 2023-10-26 | — | — | WO | disclosed |
| CN-108892640-B | Method for efficiently and environmentally preparing quinolone saxacin medicament | 云南民族大学 | 2021-05-18 | — | — | CN | disclosed |
| CN-110552018-B | Method for synthesizing 1-naphthol compound based on electrochemical intermolecular cyclization | 广西师范大学 | 2021-03-05 | — | — | CN | disclosed |
| CN-107548397-B | Kv1.3 inhibitors and medical uses thereof | 4SC股份公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-107548396-B | Kv1.3 inhibitors and medical uses thereof | 4SC股份公司 | 2020-04-28 | — | — | CN | disclosed |
| CN-110552018-A | Method for synthesizing 1-naphthol compound based on electrochemical intermolecular cyclization | UNIV GUANGXI NORMAL | 2019-12-10 | — | — | CN | disclosed |
| CN-107548397-A | Kv1.3 inhibitors and medical uses thereof | 4SC股份公司 | 2018-01-05 | — | — | CN | disclosed |
| CN-107548396-A | Kv1.3 inhibitors and medical uses thereof | 4SC股份公司 | 2018-01-05 | — | — | CN | disclosed |
| CN-102605034-B | Biological enzyme resolution method for preparing optically pure (S)-5-(4-fluorophenyl)-5-hydroxypentanoate | CHONGQING HUIJIAN BIOLOG TECHNOLOGY CO LTD | 2014-05-14 | — | — | CN | disclosed |
| CN-102605034-A | Biological enzyme resolution method for preparing optically pure (S)-5-(4-fluorophenyl)-5-hydroxypentanoate | CHONGQING HUIJIAN BIOLOG TECHNOLOGY CO LTD | 2012-07-25 | — | — | CN | disclosed |
| EP-1608631-A2 | BI-CYCLIC PYRIMIDINE INHIBITORS OF TGF BETA | SCIOS INC. (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1509225-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | Wyeth (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20050004143-A1 | Bi-cyclic pyrimidine inhibitors of TGFbeta | SCIOS, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004087056-A2 | BI-CYCLIC PYRIMIDINE INHIBITORS OF TGFβ | SCIOS INC. (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | WYETH (US) | 2004-04-29 | — | — | US | disclosed |
| WO-2003099275-A1 | METHOD FOR THE USE OF PYRANOINDOLE DERIVATIVES TO TREAT INFECTION WITH HEPATITIS C VIRUS | WYETH (US) | 2003-12-04 | — | — | WO | disclosed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
| US-4055566-A | ANTIINFLAMMATORY | SANDOZ, INC. (US) | 1977-10-25 | — | — | US | disclosed |
| US-4017499-A | ANTIINFLAMMATORY | SANDOZ, INC. (US) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082643-A1 | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus | HAVCR2, HCCS, ZC3HAV1 | ALDH1A1 495/4885KDM4E 2244/4885F2R 579/4885 |
| US-20050004143-A1 | Bi-cyclic pyrimidine inhibitors of TGFbeta | TYMP, TYMS, TGFBR1 | ALDH1A1 2042/4885KDM4E 2202/4885F2R 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.